<DOC>
	<DOC>NCT03071068</DOC>
	<brief_summary>This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST) in subjects with centre-involved diabetic macular oedema (DME).</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Male or female aged 18 years or older Type 1 or type 2 diabetes Centreinvolved DME with CST ≥ 340µm on Spectralis SDOCT or ≥ 320µm on nonSpectralis SD OCT, in the study eye Reduced vision primarily due to DME, with BCVA between 72 and 23 ETDRS letters read at 4 meters (20/40 and 20/320 Snellen equivalent) in the study eye Antivascular endothelial growth factor (antiVEGF) treatment naïve study eye or poor response to prior antiVEGF treatment in the study eye Nonproliferative diabetic retinopathy, or stable proliferative diabetic retinopathy without neovacularisation at the disc Written informed consent obtained from the subject prior to screening procedures Exclusion criteria: Concurrent disease in the study eye, other than DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results Previous treatments / procedures in the study eyes as follows, or their planned use during the THR317 treatment period for up to 30 days after the last injection: panretinal or focal / grid laser photocoagulation [3 months], antiVEGF treatment [any time for antiVEGF naïve subjects; 4 weeks for subjects with a poor response to antiVEGF treatment], intraocular or periocular corticosteroids [4 months], steroid implant [any time], intraocular surgery [3 months], vitrectomy [any time] Any active ocular / intraocular infection or inflammation in either eye Aphakic study eye Untreated diabetes Glycated haemoglobin A (HbA1c) &gt; 12% Uncontrolled hypertension in the opinion of the Investigator Pregnant or lactating female or female of childbearing potential not utilising an adequate form of contraception or male of reproductive potential not utilising contraception suggesting lens / zonular instability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>